Table 1.
T he main characteristics of the included studies.
| Author/Year | Arms | Blinding | Body mass index | Waist circumference | Male | Sample(N) | Intervention (Dose) | Study duration | Outcome evaluation | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLP-1 RAs | Control | GLP-1 RAs | Control | GLP-1 RAs | Control | GLP-1 RAs | Control | GLP-1 RAs | Control group | |||||
| Guo et al./2020 (38) | 3 | No | 29.2± 4.2 | 28.6± 3.7 | 95.5± 8.0 | 98.6± 7.3 | 16 | 20 | 31 | 30 | Liraglutide(max 1.8mg qd) | Placebo | 26 | 1H-MRS |
| Guo et al./2020 (38) | 3 | No | 29.2± 4.2 | 28.3± 3.8 | 95.5± 8.0 | 96.3± 7.6 | 16 | 18 | 31 | 30 | Liraglutide(max 1.8mg qd) | Insulin | 26 | 1H-MRS |
| Kuchay et al./2020 (39) | 2 | Yes | 29.6± 3.6 | 29.9± 3.9 | _ | _ | 13 | 12 | 32 | 32 | Dulaglutide(max 1.5mg qw) | Usual care | 24 | MRI-PDFF |
| Liu et al./2020 (40) | 2 | No | 28.49 ± 3.02 | 27.84 ± 3.10 | 97.17 ± 9.35 | 97.33± 9.20 | 16 | 17 | 35 | 36 | Exenatide(19.43 ± 2.36ug qd) | Insulin(16.97 ± 8.83 IU) | 24 | MRS |
| Zhang et al./2020 (43) | 2 | Yes | 27.6± 5.2 | 27.1± 3.8 | 93.2 ± 4.6 | 91.6± 7.2 | 13 | 15 | 30 | 30 | Liraglutide(max 1.2mg qd) | Pioglitazone(max 30mg qd) | 24 | 1H-MRS |
| Yan et.al/2019 (42) | 3 | No | 30.1± 3.3 | 29.6± 3.5 | 101.7 ± 7.9 | 102.9± 9.9 | 17 | 14 | 24 | 24 | Liraglutide(max 1.8mg qd | Insulin | 26 | MRI-PDFF |
| Yan-1 et.al/2019 (42) | 3 | No | 30.1± 3.3 | 29.7± 2.8 | 101.7 ± 7.9 | 102.8± 8.3 | 17 | 21 | 24 | 27 | Liraglutide(max 1.8mg qd | Sitagliptin(100mg qd) | 26 | MRI-PDFF |
| Smits et.al/2016 (41) | 3 | Yes | 32.8± 1.0 | 30.6± 0.7 | _ | _ | 8 | 9 | 17 | 17 | Liraglutide(max 1.8mg qd) | Placebo | 12 | 1H-MRS |
| Smits-1 et.al/2016 (41) | 3 | Yes | 32.8± 1.0 | 32.8± 1.0 | _ | _ | 8 | 10 | 17 | 17 | Liraglutide(max 1.8mg qd) | Sitagliptin(100mg qd) | 12 | 1H-MRS |
| Tang et.al/2015 (44) | 2 | Yes | 31.3 ± 6 4.1 | 31.2 ± 6 5.0 | 107.0± 10.6 | 105.4± 11.0 | 11 | 11 | 18 | 17 | Liraglutide(max 1.8mg qd) | Insulin | 12 | MRI+MRI-PDFF |
| Bi et al./2014 (37) | 3 | No | 25.1± 1.1 | 24.5± 0.6 | 93.2± 2.5 | 89.5± 1.9 | 7 | 4 | 11 | 11 | Exenatide(max 10ug bid) | Insulin | 24 | 1H-MRS |
| Bi et al./2014 (37) | 3 | No | 25.1± 1.1 | 23.9± 1.0 | 93.2± 2.5 | 87.3± 2.4 | 7 | 5 | 11 | 11 | Exenatide(max 10ug bid) | Pioglitazone(max 45mg qd) | 24 | 1H-MRS |
GLP-1 RAs, Glucagon Like Peptide-1 receptor agonists; MRI, magnetic resonance imaging; 1H-MRS, magnetic resonance spectroscopy; MRI-PDFF proton density fat fraction was measured by MRS.